Phreesia, Inc. (NYSE:PHR - Get Free Report) Director Michael Weintraub sold 2,569 shares of the stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $27.86, for a total transaction of $71,572.34. Following the completion of the transaction, the director now owns 143,039 shares of the company's stock, valued at approximately $3,985,066.54. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Michael Weintraub also recently made the following trade(s):
- On Monday, June 9th, Michael Weintraub sold 7,431 shares of Phreesia stock. The shares were sold at an average price of $27.51, for a total transaction of $204,426.81.
Phreesia Trading Down 2.4%
Shares of PHR stock traded down $0.64 on Friday, reaching $25.99. 448,368 shares of the company's stock were exchanged, compared to its average volume of 443,599. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The company's fifty day simple moving average is $25.01 and its 200 day simple moving average is $25.77. The stock has a market capitalization of $1.55 billion, a PE ratio of -17.68 and a beta of 0.68. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $30.53.
Phreesia (NYSE:PHR - Get Free Report) last announced its earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The firm's revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.05) EPS. As a group, analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current year.
Analysts Set New Price Targets
PHR has been the topic of several research analyst reports. KeyCorp dropped their target price on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Citigroup reaffirmed a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. DA Davidson reduced their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Phreesia in a research report on Thursday, March 13th. Finally, Truist Financial upped their price objective on shares of Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Twelve analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $31.64.
View Our Latest Report on PHR
Institutional Investors Weigh In On Phreesia
Several large investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in Phreesia by 83.6% during the third quarter. Barclays PLC now owns 94,929 shares of the company's stock worth $2,163,000 after purchasing an additional 43,225 shares in the last quarter. Rhumbline Advisers raised its stake in Phreesia by 7.4% in the fourth quarter. Rhumbline Advisers now owns 83,631 shares of the company's stock valued at $2,104,000 after buying an additional 5,756 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in shares of Phreesia during the fourth quarter worth about $76,000. Peregrine Capital Management LLC grew its holdings in shares of Phreesia by 0.8% during the fourth quarter. Peregrine Capital Management LLC now owns 319,327 shares of the company's stock worth $8,034,000 after purchasing an additional 2,531 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Phreesia by 23.5% during the fourth quarter. Handelsbanken Fonder AB now owns 12,600 shares of the company's stock worth $317,000 after purchasing an additional 2,400 shares during the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.
Phreesia Company Profile
(
Get Free Report)
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles

Before you consider Phreesia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phreesia wasn't on the list.
While Phreesia currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.